Mitra Biotech, a translational biology company focused on enabling personalized cancer care and rational drug development, has announced the addition of Dr. Eric Rowinsky to its Scientific Advisory Board.
Dr. Eric Rowinsky was previously the Chief Medical Officer for ImClone Systems. Dr. Rowinsky is currently the Chief Medical Officer and Head of Research and Development of Stemline Therapeutics, Inc. Dr. Rowinsky has more than 25 years of experience managing clinical trials and developing drugs in oncology, including leading FDA approval of Erbitux® and advancing eight other biological cancer therapeutics while at ImClone.
Help employers find you! Check out all the jobs and post your resume.
